New drug eRapa aims to delay surgery in High-Risk FAP patients
Disease control
Recruiting now
This study tests whether the drug eRapa can slow down disease progression in adults with Familial Adenomatous Polyposis (FAP), a condition that causes many polyps in the gut and raises cancer risk. About 168 participants will take eRapa or a placebo daily every other week, with r…
Phase: PHASE3 • Sponsor: Rapamycin Holdings Inc. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC